RBC Irradiation, Anemia and Gut Injury (RBC-mNIRS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02741648 |
Recruitment Status : Unknown
Verified April 2021 by Cassandra D Josephson, Emory University.
Recruitment status was: Recruiting
First Posted : April 18, 2016
Last Update Posted : April 21, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Anemia Necrotizing Enterocolitis | Device: Near Infrared Spectroscopy |
Anemia and digestive tract complications are common problems in Extremely Low Birth Weight infants. Anemia is a condition in which the body does not have enough red blood cells (RBC). RBCs are important because they contain hemoglobin, the substance that carries oxygen throughout the body. Transfusions of RBCs in these infants is frequently required to correct the anemia. Oxygen levels in the digestive tract will be measured before, during and after each blood transfusion using a tissue oxygen monitor called Near Infrared Spectroscopy (NIRS). By using this technology, better understanding can be obtained of intestinal blood flow patterns.
In addition, ELBW infants are more likely to have immature digestive systems and are at risk for digestive tract problems such as necrotizing enterocolitis (NEC). NEC is a disease characterized by infection and decreased blood flow to the intestines. NEC is a major cause of devastating illness and death in this vulnerable preterm population. Leftover blood samples, urine, stool, and breast milk samples will be collected, frozen, and stored. In the event a baby develops a digestive tract complication they will be studied in a laboratory to identify markers that indicate a healthy digestive tract versus illness.
Study Type : | Observational |
Estimated Enrollment : | 220 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Red Blood Cell Transfusion and Digestive Tract Oxygenation in Preterm Infants Weighing ≤ 1250 Grams |
Study Start Date : | July 2016 |
Estimated Primary Completion Date : | April 2022 |
Estimated Study Completion Date : | April 2022 |

Group/Cohort | Intervention/treatment |
---|---|
ELBW Infants with Prolonged Irradiation Storage Time
Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
|
Device: Near Infrared Spectroscopy
INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
Other Name: NIRS |
ELBW Infants without Irradiation Storage
Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
|
Device: Near Infrared Spectroscopy
INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
Other Name: NIRS |
ELBW Infants with NEC
Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as "Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy.
|
Device: Near Infrared Spectroscopy
INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
Other Name: NIRS |
ELBW Infants without NEC
Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
|
Device: Near Infrared Spectroscopy
INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
Other Name: NIRS |
- Changes in Mesenteric Tissue Oxygenation [ Time Frame: 60 Minutes prior to transfusion to 48 hours after transfusion ]Regional Oxygenation Saturation Levels (rSO2) are measured via the INVOS 5100C Cerebral/Somatic Oximeter by applying an adhesive sensor probe to the patient's periumbilical area for mesenteric monitoring.
- Changes in Mesenteric Tissue Oxygenation [ Time Frame: Week 30 to Week 34 Post Menstrual Age ]ELBW infants that reach the window when NEC typically occurs will be further compared as those with vs without anemia. Regional Oxygenation Saturation Levels (rSO2) are measured via the INVOS 5100C Cerebral/Somatic Oximeter by applying an adhesive sensor probe to the patient's periumbilical area for mesenteric monitoring. NIRS will be performed once per week (whether transfused or not) for a 48 hour period starting each Monday (day of routine lab draw to evaluate anemia).
Biospecimen Retention: Samples Without DNA
Residual patient blood samples (obtained for routine clinical testing), urine, stool and breast milk will be collected, frozen and stored. If a baby develops a digestive tract complication, the stored specimens will be studied in the laboratory in an effort to identify markers of a healthy digestive tract versus illness.
A sample of transfused RBCs will be obtained from the RBC unit at each RBC transfusion. If the baby develops a digestive tract complication the stored specimens will be studied in the laboratory to identify changes in the biochemical compounds of the transfused blood that may have taken place over time.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Day to 5 Days (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Birth weight ≤1250 grams
- Postnatal age within 7 days of birth
Exclusion Criteria:
- Infant not expected to live beyond 7 days of life based on assessment of treating neonatologist
- Severe congenital abnormality expected to affect life expectancy
- RBC or platelet transfusion at an outside institution occurring prior to screening
- Maternal refusal to participate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02741648
Contact: Cassandra Josephson, MD | 404-785-4553 | cjoseph@emory.edu | |
Contact: Hailly Butler, RN | 404 712-8895 | hailly.butler@emory.edu |
United States, Georgia | |
Grady Memorial Hospital | Recruiting |
Atlanta, Georgia, United States, 30303 | |
Contact: Cassandra Josephson, MD 404-785-4553 cjoseph@emory.edu | |
Contact: Hailly Butler, RN 404 712-8895 hailly.butler@emory.edu | |
Principal Investigator: Cassandra Josephson, MD | |
Emory University Hospital Midtown | Recruiting |
Atlanta, Georgia, United States, 30308 | |
Contact: Cassandra Josephson, MD 404-785-4553 cjoseph@emory.edu | |
Contact: Hailly Butler, RN 404 712-8895 hailly.butler@emory.edu | |
Principal Investigator: Cassandra Josephson, MD | |
Northside Hospital - Neonatology | Recruiting |
Atlanta, Georgia, United States, 30342 | |
Contact: Michael Hinkes, MD 404-785-4553 Mike_Hinkes@pediatrix.com | |
Contact: Katrina Grier khgrier@gmail.com | |
Sub-Investigator: Michael Hinkes, MD |
Principal Investigator: | Cassandra Josephson, MD | Emory University |
Responsible Party: | Cassandra D Josephson, Professor, Emory University |
ClinicalTrials.gov Identifier: | NCT02741648 |
Other Study ID Numbers: |
IRB00083691 2P01HL086773 ( U.S. NIH Grant/Contract ) 1R01HL138714 ( U.S. NIH Grant/Contract ) |
First Posted: | April 18, 2016 Key Record Dates |
Last Update Posted: | April 21, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Red Blood Cell Transfusion Digestive tract problems Extremely Low Birth Weight |
Enterocolitis Enterocolitis, Necrotizing Anemia Hematologic Diseases |
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |